Since plasma TGF-β1 levels may serve as a biomarker to assess clinical activity of galunisertib in future randomized trials in a larger HCC population, we assessed the rapidity of the onset of TGF-β1 response (S1 Fig, Table 2). Here, TGFB1 is linked to hepatocellular carcinoma.